AbClon Removed from KOSDAQ Watchlist... "Accelerating CAR-T Therapy Development"

Market Cap Requirement Met, Sales Requirement Exempted
Pipeline Expansion with AT101 and AT501
CEO Lee Jongseo: "Not the End, but a New Beginning"

AbClon, a company specializing in antibody-based therapeutics, has been removed from the KOSDAQ watchlist.

According to the financial investment industry on March 16, AbClon was officially removed from the KOSDAQ watchlist as of this day after submitting an audit report with an "unqualified" opinion from an external auditor.

AbClon explained that although it was previously designated as a watchlisted stock for failing to meet the sales requirement, the recent market capitalization exceeded 60 billion won, which is the exemption standard under KOSDAQ regulations, thus resolving the related risk.

On this day, AbClon CEO Lee Jongseo stated in a letter to shareholders, "Being removed from the watchlist is not the end but a new beginning," adding, "We will actively communicate with shareholders and enhance corporate value through research and development achievements."

AbClon is currently developing the chimeric antigen receptor T-cell (CAR-T) therapy 'AT101' for hematologic malignancies, the solid tumor CAR-T therapy 'AT501', and bispecific antibody candidates 'AM105' and 'AM109.' The company is also conducting research on next-generation in-vivo CAR-T technology.

The company further explained that, through collaboration with its Chinese partner, Henlius, related clinical trials are being expanded and pipeline development is ongoing.

This content was produced with the assistance of AI translation services.